{"id":72271,"date":"2026-08-11T12:52:53","date_gmt":"2026-08-11T04:52:53","guid":{"rendered":"https:\/\/flcube.com\/?p=72271"},"modified":"2026-08-11T12:52:54","modified_gmt":"2026-08-11T04:52:54","slug":"cspc-pharmaceutical-groups-monkeypox-mrna-vaccine-sys6037-receives-fda-approval-to-conduct-clinical-trials-in-the-us","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72271","title":{"rendered":"CSPC Pharmaceutical Group&#8217;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>)<\/strong> announced that its <strong>Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine)<\/strong> has received approval from the <strong>US Food and Drug Administration (FDA)<\/strong> to conduct clinical trials in the US. The product was developed in collaboration with the <strong>Institute of Microbiology, Chinese Academy of Sciences<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-overview\" class=\"wp-block-heading\">Regulatory Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>CSPC Pharmaceutical Group Limited (HKG: 1093)<\/td><\/tr><tr><td><strong>Collaborator<\/strong><\/td><td>Institute of Microbiology, Chinese Academy of Sciences<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYS6037 injection (monkeypox mRNA vaccine)<\/td><\/tr><tr><td><strong>Product Category<\/strong><\/td><td>Category 1 preventive biologic product<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>US Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Clearance to conduct clinical trials in the US<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-sys6037\" class=\"wp-block-heading\">Product Profile \u2013 SYS6037<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> <strong>mRNA vaccine<\/strong> \u2014 a <strong>multi\u2011antigen monkeypox vaccine encoded by a single mRNA strand<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> Prevention of monkeypox<\/li>\n\n\n\n<li><strong>Design Advantage:<\/strong> Single\u2011strand encoding of multiple antigens enables a streamlined, potentially scalable vaccine construct<\/li>\n\n\n\n<li><strong>Platform Significance:<\/strong> Extends CSPC Pharmaceutical Group&#8217;s mRNA technology platform into the infectious disease vaccine space<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pre-clinical-evidence\" class=\"wp-block-heading\">Pre\u2011Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Comparator<\/strong><\/td><td>Live\u2011attenuated vaccine (Tiantan strain)<\/td><\/tr><tr><td><strong>Immunogenicity<\/strong><\/td><td><strong>Superior<\/strong> to the live\u2011attenuated comparator<\/td><\/tr><tr><td><strong>Protective Efficacy<\/strong><\/td><td><strong>Superior<\/strong> to the live\u2011attenuated comparator<\/td><\/tr><tr><td><strong>Cross\u2011Reactivity<\/strong><\/td><td>Broad\u2011spectrum cross\u2011reactivity against various <strong>Orthopoxvirus<\/strong> antigens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pre\u2011clinical studies demonstrated that, compared with the live\u2011attenuated vaccine (Tiantan strain), SYS6037 exhibited <strong>superior immunogenicity and protective efficacy<\/strong>, and displayed <strong>broad\u2011spectrum cross\u2011reactivity against various Orthopoxvirus antigens<\/strong> \u2014 positioning it as a potentially competitive monkeypox vaccine product in the market.<\/p>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Clinical Entry:<\/strong> FDA clearance to conduct clinical trials in the US marks a significant international regulatory milestone for a China\u2011developed monkeypox vaccine, opening a path into one of the world&#8217;s most rigorous regulatory jurisdictions.<\/li>\n\n\n\n<li><strong>Next\u2011Generation Design:<\/strong> As an <strong>mRNA\u2011based, multi\u2011antigen, single\u2011strand<\/strong> vaccine, SYS6037 offers a modern alternative to traditional live\u2011attenuated vaccines, with potential advantages in immunogenicity, safety profile and manufacturing flexibility.<\/li>\n\n\n\n<li><strong>Broad\u2011Spectrum Potential:<\/strong> Cross\u2011reactivity against multiple <strong>Orthopoxvirus<\/strong> antigens suggests SYS6037 could offer protection beyond a single monkeypox strain \u2014 a meaningful differentiator given global concerns over poxvirus emergence and variant evolution.<\/li>\n\n\n\n<li><strong>Academic\u2011Industry Collaboration:<\/strong> The partnership with the <strong>Institute of Microbiology, Chinese Academy of Sciences<\/strong> underscores the model of translating academic research into clinically validated vaccine candidates.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SYS6037&#8217;s clinical development in the US, regulatory outcomes, and commercial potential. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000882_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026081000882_c.\"><\/object><a id=\"wp-block-file--media-09314c15-d67b-4470-8e0d-bc0576cfa493\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000882_c.pdf\">2026081000882_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081000882_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-09314c15-d67b-4470-8e0d-bc0576cfa493\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,171,855,12],"class_list":["post-72271","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Group&#039;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72271\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Group&#039;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72271\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T04:52:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T04:52:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Group&#8217;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US\",\"datePublished\":\"2026-08-11T04:52:53+00:00\",\"dateModified\":\"2026-08-11T04:52:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271\"},\"wordCount\":424,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72271#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72271\",\"name\":\"CSPC Pharmaceutical Group's Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-11T04:52:53+00:00\",\"dateModified\":\"2026-08-11T04:52:54+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72271\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72271#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Group&#8217;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Group's Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72271","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Group's Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.","og_url":"https:\/\/flcube.com\/?p=72271","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-11T04:52:53+00:00","article_modified_time":"2026-08-11T04:52:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72271#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72271"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Group&#8217;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US","datePublished":"2026-08-11T04:52:53+00:00","dateModified":"2026-08-11T04:52:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72271"},"wordCount":424,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72271#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72271","url":"https:\/\/flcube.com\/?p=72271","name":"CSPC Pharmaceutical Group's Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-11T04:52:53+00:00","dateModified":"2026-08-11T04:52:54+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037 injection (monkeypox mRNA vaccine) has received approval from the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The product was developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72271#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72271"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72271#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Group&#8217;s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72271"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72271\/revisions"}],"predecessor-version":[{"id":72273,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72271\/revisions\/72273"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}